Stop wasting time looking for the right stocks. Free training on how to find perfect stock trades that can move 300-1,500%. Learn the # 1 key to successful stock investing and how to find success even If the market is crashing, rebounding… or just going sideways. (ad)
Do Not Delay - Click Here Now
Buy Price: $21.00 or better Sell Price: TradersPro Sell Signal TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest […]
Read MorePlus, the U.S. reported a record number of new confirmed coronavirus cases, the FAA and Boeing completed the test flights of the 737 Max, Tesla is up after saying it delivered 90,650 vehicles in the second quarter, and PG&E shares are up after the utility emerges from bankruptcy.
Read MorePlus, ADP said private payrolls grew by 2.369 million in June, United Airlines said it is adding 25,000 flights next month, and Beyond Meat is rising after news its meatless burger patties will soon be available in grocery stores in China.
Read MorePlus, coronavirus cases surpassed 10 million globally and 2.5 million in the U.S., Chesapeake Energy filed for bankruptcy, and Beyond Meat shares are down after a double downgrade.
Read MoreTrade Setup Buy Target $36.90 Sell Target $45.42 Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company’s lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men […]
Read MoreBuy Price: $6.25 or better Sell Price: TradersPro Sell Signal IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic […]
Read MoreTrade Setup Buy Target $10.43 Sell Target $12.34 CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer.
Read MorePlus, stocks are up after President Trump said the U.S.-China phase one trade deal is still “fully intact” after confusion following a statement from trade advisor Peter Navarro, six global investors inked a $20.7 billion agreement with the Abu Dhabi National Oil Company, and Wirecard’s former CEO has been arrested.
Read MorePlus, Gilead is gearing up to test an inhaled version of its antiviral drug remdesivir in the treatment of COVID-19, Microsoft is acquiring a cybersecurity startup, and Wirecard shares tanked after it said the $2.1 billion missing from its balance sheet likely doesn’t exist.
Read MoreTrade Setup Buy Target $31.63 Sell Target $36.42 Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic […]
Read MoreThere are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Companys software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.